RhumbLine Advisers’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
RhumbLine Advisers's BEAM Position: Q3 2026 in Review
RhumbLine Advisers increased its Beam Therapeutics (BEAM) stake by 4.5% in Q3 2026, buying an estimated $164K and bringing the position to 138,124 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1631.
RhumbLine Advisers first reported a position in BEAM in Q1 2020 and has held it in 27 quarters since. The position peaked at $6.27M in Q2 2021. 196 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- RhumbLine Advisers held 138,124 shares of Beam Therapeutics worth $3.38M as of Q3 2026.
- RhumbLine Advisers bought 5,897 Beam Therapeutics shares in Q3 2026, an estimated $164K.
- Beam Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #1631 holding.
- RhumbLine Advisers first reported a position in Beam Therapeutics in Q1 2020 and has held it in 27 quarters since.
- RhumbLine Advisers's Beam Therapeutics position peaked at $6.27M in Q2 2021.
- 196 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.